Sania Therapeutics
Targeted gene therapy for dysfunctional neural circuits
Sania has developed a gene-therapy platform to selectively target dysfunctional neural circuits in a more selective and safer manner than previously possible. The company has demonstrated in-vivo proof of concept and is preparing for IND-enabling studies.
Technology
How they’re delivering breakthroughs
- Precision delivery of gene therapy only to affected neural circuits
- Advantageous therapeutic window lays the foundation for neural gene therapies to become standard of care
- Several pipeline programmes are underway
Impact
How they’re making a difference
- Severe spasticity as a lead indication, which has no effective treatment and affects over 2M people US/EU alone
- Wide applicability across conditions relying on neural control such as hypertension or neuropathic pain
